Velphoro

1. For the treatment of hyperphosphatemia associated with end-stage renal disease (ESRD) where patients are on dialysis and have a sustained1 serum phosphate > 1.8 mmol/L AND serum calcium > 2.65 mmol/L;
   
   OR

2. For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery calcification. 

Note: Dialysis patients with hyperphosphatemia meeting the above criteria who are experiencing other types of calcification (e.g., aortic) in the absence of coronary artery calcification may be considered case-by-case by faxing your request to the EAP. 

Calcium and phosphate levels provided to demonstrate sustained elevations should be at least 4 weeks apart. 

Exclusion criteria:
Patients with haemochromatosis or any other iron accumulation disorders.

Duration of Approval: Lifetime